Pfizer seeks to market palbociclib in ER+/HER- breast cancer
This article was originally published in Scrip
Executive Summary
As expected, Pfizer submitted its new drug application (NDA) to the FDA for palbociclib seeking approval of the drug in breast cancer based on Phase II data from the firm's PALOMA-1 trial.